Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. (Q34558187)

PubMed publication ID

3 August 2017

0 references

1 reference

title

Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6481463&resulttype=core&format=json

14 May 2020

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6481463&resulttype=core&format=json

14 May 2020

Jennifer R. Evans

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6481463&resulttype=core&format=json

14 May 2020

author name string

Mariacristina Parravano

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6481463&resulttype=core&format=json

14 May 2020

Iris Gordon

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6481463&resulttype=core&format=json

14 May 2020

Ersilia Lucenteforte

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6481463&resulttype=core&format=json

14 May 2020

publication date

22 June 2017

1 reference

PubMed publication ID

28639415

Cochrane Database of Systematic Reviews

3 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6481463&resulttype=core&format=json

14 May 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6481463&resulttype=core&format=json

14 May 2020

page(s)

CD007419

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6481463&resulttype=core&format=json

Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial

14 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Structural and functional measures of efficacy in response to bevacizumab monotherapy in diabetic macular oedema: exploratory analyses of the BOLT study (report 4).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Cost-effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Expanded 2-Year Follow-up of Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Intravitreal aflibercept for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Changes in Vision- and Health-Related Quality of Life in Patients with Diabetic Macular Edema Treated with Pegaptanib Sodium or Sham

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

A Phase 2/3, Multicenter, Randomized, Double-Masked, 2-Year Trial of Pegaptanib Sodium for the Treatment of Diabetic Macular Edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

The REVEAL Study: Ranibizumab Monotherapy or Combined with Laser versus Laser Monotherapy in Asian Patients with Diabetic Macular Edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Long-term effects of ranibizumab on diabetic retinopathy severity and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Changes in vision related quality of life in patients with diabetic macular edema: ranibizumab or laser treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

A Crossover Design for Comparative Efficacy: A 36-Week Randomized Trial of Bevacizumab and Ranibizumab for Diabetic Macular Edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Intravitreal fasudil combined with bevacizumab for persistent diabetic macular edema: a novel treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Intravitreal bevacizumab injection alone or combined with macular photocoagulation compared to macular photocoagulation as primary treatment of diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

The pathogenesis of edema in diabetic maculopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular edema: results of the Pan-american Collaborative Retina Study Group at 24 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Bevacizumab versus ranibizumab: why are we not playing the joker?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Detection of diabetic foveal edema: contact lens biomicroscopy compared with optical coherence tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Diabetic macular edema: what is focal and what is diffuse?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Graphical tools for network meta-analysis in STATA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Ranibizumab for the treatment of wet AMD: a summary of real-world studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Corticosteroids in posterior segment disease: an update on new delivery systems and new indications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Checking consistency in mixed treatment comparison meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Intravitreal steroids for macular edema in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

GRADE guidelines 6. Rating the quality of evidence—imprecision

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Revolution to a new standard treatment of diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Treatment Patterns of Anti-Vascular Endothelial Growth Factor and Laser Therapy Among Patients with Diabetic Macular Edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Systematic review and mixed treatment comparison of intravitreal aflibercept with other therapies for diabetic macular edema (DME)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Intravitreous dexamethasone effects on different patterns of diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Improving the economic value of photographic screening for optical coherence tomography-detectable macular oedema: a prospective, multicentre, UK study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

A randomized clinical trial comparing fixed vs pro-re-nata dosing of Ozurdex in refractory diabetic macular oedema (OZDRY study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

A 2-Year, Phase IV, Multicentre, Observational Study of Ranibizumab 0.5 mg in Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice: The EPICOHORT Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Real-World Outcomes of Ranibizumab Treatment for Diabetic Macular Edema in a United Kingdom National Health Service Setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Efficacy of anti-VEGF and laser photocoagulation in the treatment of visual impairment due to diabetic macular edema: a systematic review and network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Evaluating the quality of evidence from a network meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Counterfeit Avastin in India: Punish the Criminals, Not the Patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Global prevalence and major risk factors of diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

The Efficacy and Safety of Current Treatments in Diabetic Macular Edema: A Systematic Review and Network Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Anti-vascular endothelial growth factor for diabetic macular oedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Three-Year Outcomes of Individualized Ranibizumab Treatment in Patients with Diabetic Macular Edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Evaluating the Quality of Evidence from a Network Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

Treatment of macular edema in diabetic retinopathy: comparison of the efficacy of intravitreal bevacizumab and ranibizumab injections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB5

21 January 2018

1 reference

12 December 2020

1 reference

12 December 2020

Angiogenic pathways in diabetic retinopathy

1 reference

12 December 2020

How to identify randomized controlled trials in MEDLINE: ten years on

1 reference

12 December 2020

Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema.

1 reference

12 December 2020

The evidence provided by a single trial is less reliable than its statistical analysis suggests

1 reference

12 December 2020

Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema

1 reference

12 December 2020

Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial

1 reference

12 December 2020

Optical coherence tomography for age-related macular degeneration and diabetic macular edema: an evidence-based analysis

1 reference

12 December 2020

Comparison of intravitreal bevacizumab, intravitreal triamcinolone acetonide, and macular grid augmentation in refractory diffuse diabetic macular edema: A prospective, randomized study

1 reference

12 December 2020

Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study

1 reference

12 December 2020

A randomized trial to assess functional and structural effects of ranibizumab versus laser in diabetic macular edema (the LUCIDATE study).

1 reference

12 December 2020

[Japan phase 3 study of pegaptanib sodium in patients with diabetic macular edema]

1 reference

12 December 2020

Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA).

1 reference

12 December 2020

Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group

1 reference

12 December 2020

The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema

1 reference

12 December 2020

10.1002/14651858.CD007419.PUB5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6481463&resulttype=core&format=json

14 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6481463&resulttype=core&format=json

14 May 2020

PubMed publication ID

28639415

1 reference